The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
List view / Grid view
Sumitomo Dainippon Pharma
The A2a receptor antagonist, which aims to inhibit the immunosuppression of T cells by adenosine, was in part designed using Exscientia’s 3D evolutionary artificial intelligence platform.
The developers of DSP-1181, a drug created using AI, announced that it has entered a Phase I clinical trial for the treatment of obsessive-compulsive disorder (OCD).